LEXX earnings date and last-quarter result: next report 2026-10-28, last quarter miss, P/E -1.58. Updated 2026-07-23.
Lexaria Bioscience (LEXX) Research Hub
Lexaria Bioscience (LEXX) trades on NASDAQ, CA in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 2.92 USD (-5.19%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.58, market cap 0.01B. This hub links to the full technical, earnings and options research available for LEXX.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, CA |
| Last close | 2.92 USD (-5.19%) |
| 52-week range | 2.43 USD – 14.37 USD |
| Trend regime | Range |
| 14-day RSI | 43.2 (Bearish) |
| Trailing P/E | -1.58 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
| Next earnings | 2026-10-28 |
Available research for LEXX
Covered Call on LEXX: how it works, illustrative setup around the real 2.92 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on LEXX: how it works, illustrative setup around the real 2.92 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on LEXX: how it works, illustrative setup around the real 2.92 USD price, max profit/loss, breakeven and when to use it. Educational.
LEXX technical analysis: range, last 2.92 USD, RSI 43.2, 52w range 2.43 USD–14.37 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is LEXX in?
Lexaria Bioscience (LEXX) is classified under Healthcare (Biotechnology), listed on NASDAQ, CA.
Is LEXX in an uptrend or downtrend?
As of 2026-10-26, LEXX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is LEXX's trailing P/E ratio?
LEXX's trailing P/E is -1.58, with a market cap of 0.01B. See the earnings research page for full valuation detail.
When does LEXX next report earnings?
LEXX is next scheduled to report earnings on 2026-10-28.